Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report) and Comera Life Sciences (NASDAQ:CMRA – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, valuation and dividends.
Profitability
This table compares Bolt Biotherapeutics and Comera Life Sciences’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Bolt Biotherapeutics | -556.59% | -51.74% | -37.70% |
Comera Life Sciences | N/A | N/A | N/A |
Insider & Institutional Ownership
86.7% of Bolt Biotherapeutics shares are held by institutional investors. 30.9% of Bolt Biotherapeutics shares are held by company insiders. Comparatively, 8.9% of Comera Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Bolt Biotherapeutics | 0 | 5 | 0 | 0 | 2.00 |
Comera Life Sciences | 0 | 0 | 0 | 0 | N/A |
Bolt Biotherapeutics presently has a consensus price target of $3.50, suggesting a potential upside of 404.40%.
Valuation and Earnings
This table compares Bolt Biotherapeutics and Comera Life Sciences’ revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Bolt Biotherapeutics | $11.32 million | 2.34 | -$69.20 million | ($1.66) | -0.42 |
Comera Life Sciences | $1.00 million | 0.00 | -$18.00 million | ($0.49) | N/A |
Comera Life Sciences has lower revenue, but higher earnings than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Comera Life Sciences, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Bolt Biotherapeutics has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, Comera Life Sciences has a beta of 0.13, meaning that its stock price is 87% less volatile than the S&P 500.
Summary
Comera Life Sciences beats Bolt Biotherapeutics on 5 of the 9 factors compared between the two stocks.
About Bolt Biotherapeutics
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
About Comera Life Sciences
Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.
Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.